Active surveillance for low-risk prostate cancer: well established, yet avoided?
Cent European J Urol
.
2022;75(3):290-291.
doi: 10.5173/ceju.2022.0141.
Epub 2022 Aug 24.
Authors
Roman Sosnowski
1
,
Hubert Kamecki
2
,
Jakub Dobruch
3
,
Monique J Roobol
4
,
Lionne D F Venderbos
4
,
Łukasz Nyk
2
,
Wojciech Krajewski
5
,
Tomasz Drewa
6
Affiliations
1
Department of Urogenital Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
2
2 Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
3
Department of Urology, Center of Postgraduate Medical Education, Warsaw, Poland.
4
Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
5
Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wrocław Medical University, Wrocław, Poland.
6
Department of General and Oncologic Urology, Nicolaus Copernicus Hospital, Toruń, Poland.
PMID:
36381164
PMCID:
PMC9628721
DOI:
10.5173/ceju.2022.0141
No abstract available
Keywords:
active surveillance; barriers; low-risk; prostate cancer.